Bone marrow in EDTA anticoagulated tube
Keep specimen at 4C
Other acceptable specimens include 4-7 ml blood in Gold SST tube for serum or in tube with EDTA for plasma, tissue in viral transport medium, amniotic fluid, and CSF.
Amplification and detection of conserved region of parvovirus B19 DNA structural protein genes VP1 and VP2 using TaqMan real-time PCR technology. This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
Erythema infectiosum (Fifth disease) is the most common manifestation of parvovirus B19 infection. The disease is characterized by a distinctive slapped-cheek" rash that gives the child a flushed look. The rash may also involve the limbs and trunk but can fluctuate in intensity for weeks to months with changes in temperature and exposure to sunlight. Arthralgia and arthritis is common among adults infected with parvovirus B19, particularly women. Polyarthropathy of knees, fingers, and other joints is common. In transient aplastic crisis, the patient has severe anemia characterized by lethargy, pallor, and weakness. Condition occurs as a complication in individuals with chronic hemolytic anemias. Normally lasts 7 to 10 days with complete recovery; however, can be life threatening and blood transfusions may be required to prevent death. Chronic infection resulting in severe anemia has been observed in AIDS patients. Infection during pregnancy can cause fetal hydrops, intrauterine growth retardation, congestive heart failure, and death.
If positive, results are reported as parvovirus B19 DNA detected.
Negative or no parvovirus B19 DNA detected
Ask for more information about our laboratory services.